Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice

Thrombosis and Haemostasis

Volumn 91, Issue 2, 2004, Pages 403-411

  Sier, Cornelis F M ^a,f   Nicoletti, Ines ^c   Santovito, Maria Lisa ^a   Frandsen, Thomas ^e   Aletti, Giovanni ^b   Ferrari, Augusto ^b   Lissoni, Andrea ^d   Giavazzi, Raffaella ^c   Blasi, Francesco ^a   Sidenius, Nicolai ^a  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MARIO NEGRI INST PHARMACOL RES   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e HVIDOVRE HOSPITAL   (Denmark)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Cleavage; Fragments; uPAR; Urine

Indexed keywords

CELL ADHESION MOLECULE; CHEMOATTRACTANT; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER PATIENT; CANCER TISSUE; CELL MIGRATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN URINE LEVEL; SERUM; TISSUE REPAIR; TUMOR XENOGRAFT; URINALYSIS;

EID: 10744233784     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-06-0351     Document Type: Article

References (49)

1. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implications for prognosis and therapy. Cancer Metast Rev 2003; 22 (2-3): 205-22.
2. Casslèn B, Gustavsson B, Åstedt B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur J Cancer 1991; 27 (11): 1445-8.
3. Sier CFM, Stephens RW, Bizik J, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58 (9): 1843-9.
4. Crowley CW, Cohen RL, Lucas BK, et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90 (11): 5021-5.
5. Kobayashi H, Gotoh J, Fujie M, et al. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1994; 57 (5): 727-33.
6. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56 (10): 2428-33.
7. Pedersen N, Schmitt M, Rønne E, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993; 92 (5): 2160-7.
8. Riisbro R, Stephens RW, Brünner N, et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 2001; 82 (3): 523-31.
9. Stephens RW, Pedersen AN, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997; 43 (10): 1868-76.
10. Pappot H, Høyer-Hansen G, Rønne E, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997; 33 (6): 867-72.
11. Ganesh S, Sier CF, Heerding MM, et al. Urokinase receptor and colorectal cancer survival [letter]. Lancet 1994; 344 (8919): 401-2.
12. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91 (10): 869-74.
13. Sier CF, Sidenius N, Mariani A, et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999; 79 (6): 717-22.
14. Resnati M, Guttinger M, Valcamonica S, et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15 (7): 1572-82.
15. Chavakis T, Kanse SM, Yutzy B, et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91 (7): 2305-12.
16. Resnati M, Pallavicini I, Wang JM, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002; 99 (3): 1359-64.
17. Massazza G, Lucchini V, Tomasoni A, et al. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease. Cancer Res 1991; 51 (23 Pt 1): 6358-62.
18. Brünner N, Thompson EW, Spang-Thomsen M, et al. lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer 1992; 28A (12): 1989-95.
19. Holst-Hansen C, Hamers MJ, Johannessen BE, et al. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer 1999; 81 (2): 203-11.
20. Verheijen JH, Mullaart E, Chang GT, et al. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48 (3): 266-9.
21. Sidenius N, Sier CFM, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 2000; 475 (1): 52-6.
22. Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998; 4 (4): 985-92.
23. Cailleau R, Young R, Oliv M, et al. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53 (3): 661-74.
24. Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett 2000; 470 (1): 40-46.
25. Koolwijk P, Sidenius N, Peters E, et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 2001; 97 (10): 3123-31.
26. Høyer-Hansen G, Rønne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267 (25): 18224-9.
27. Andreasen PA, Kjøller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72 (1): 1-22.
28. Casslèn B, Bossmar T, Lecander I, et al. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer 1994; 30A (9): 1302-9.
29. Pedersen H, Brünner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54 (17): 4671-5.
30. Kuhn W, Pache L, Schmalfeldt B, et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994; 55 (3 Pt 1): 401-9.
31. Verspaget HW, Sier CFM, Ganesh S, et al. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 1995; 31A (7-8): 1105-9.
32. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78 (1): 285-96.
33. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998; 79 (5): 449-54.
34. Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer [see comments]. Br Med J 1998; 316 (7134): 829-30.
35. Mustjoki S, Alitalo R, Stephens RW, et al. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. Thromb Haemost 1999; 81 (5): 705-10.
36. Young TN, Rodriguez GC, Moser TL, et al. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 1994; 170 (5 Pt 1): 1285-96.
37. Schmalfeldt B, Kuhn W, Reuning U, et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 1995; 55 (18): 3958-63.
38. Solberg H, Rømer J, Brünner N, et al. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 1994; 58 (6): 877-81.
39. Mustjoki S, Sidenius N, Sier CF, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000; 60 (24): 7126-32.
40. Ploug M, Ellis V, Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994; 33 (30): 8991-7.
41. Høyer-Hansen G, Behrendt N, Ploug M, et al. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997; 420 (1): 79-85.
42. Wagner SN, Atkinson MJ, Wagner C, et al. Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochem Cell Biol 1996; 105 (1): 53-60.
43. Walker PD, Kaushal GP, Shah SV, Meprin A, the major matrix degrading enzyme in renal tubules, produces a novel nidogen fragment in vitro and in vivo. Kidney Int 1998; 53 (6): 1673-80.
44. Chen LM, Song Q, Chao L, et al. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int 1995; 48 (3): 690-7.
45. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 1994; 79 (2): 315-28.
46. Taraboletti G, Belotti D, Borsotti P, et al. The 140-kilodalton antiangiogenic fragment of thrombospondin- 1 binds to basic fibroblast growth factor. Cell Growth Differ 1997; 8 (4): 471-9.
47. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3 (12): 932-43.
48. Fazioli F, Resnati M, Sidenius N, et al. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16 (24): 7279-86.
49. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273 (5281): 1551-5.